EP Patent

EP4719459A1 — Methods for identification and quantitation of abaloparatide and related peptide impurities

Assigned to Radius Health Inc · Expires 2026-04-08 · 0y expired

What this patent protects

Provided herein are methods of analyzing samples from batches of abaloparatide for abaloparatide and abaloparatide-related peptide impurities.

USPTO Abstract

Provided herein are methods of analyzing samples from batches of abaloparatide for abaloparatide and abaloparatide-related peptide impurities.

Drugs covered by this patent

Tymlos (ABALOPARATIDE) · Radius

Patent Metadata

Patent number: EP4719459A1
Jurisdiction: EP
Classification: —
Expires: 2026-04-08
Drug substance claim: No
Drug product claim: No
Assignee: Radius Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.